Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Marlon Arnone"'
Autor:
Marlon Arnone, Anna Stanger, Pauline Hanns, Jessica Kuebler, Elsa Goersch, Saskia Rudat, Claudia Lengerke
Publikováno v:
HemaSphere, Vol 7, p e69200f6 (2023)
Externí odkaz:
https://doaj.org/article/0e07b07e10354d9d98873fd293d434a9
Autor:
Marlon Arnone, Martina Konantz, Pauline Hanns, Anna M. Paczulla Stanger, Sarah Bertels, Parimala Sonika Godavarthy, Maximilian Christopeit, Claudia Lengerke
Publikováno v:
Cancers, Vol 12, Iss 12, p 3742 (2020)
Patients suffering from acute myeloid leukemia (AML) show highly heterogeneous clinical outcomes. Next to variabilities in patient-specific parameters influencing treatment decisions and outcome, this is due to differences in AML biology. In fact, di
Externí odkaz:
https://doaj.org/article/557c465e584449f395b08acc4edbe3b7
Publikováno v:
Blood. 140:8706-8706
Autor:
Jonas Schärer, Seiamak Bahram, Alain Dumlin, Joëlle S. Müller, Thorsten Schaefer, Claudia Lengerke, Irmgard Sinning, Marlon Arnone, Karl Welte, Christoph Schürch, Pauline Hanns, Martina Konantz, Raphael Carapito, Julia Skokowa, Klemens Wild
Publikováno v:
Blood
Blood, American Society of Hematology, 2021, 137 (10), pp.1340-1352. ⟨10.1182/blood.2020008115⟩
Blood, American Society of Hematology, 2021, 137 (10), pp.1340-1352. ⟨10.1182/blood.2020008115⟩
Heterozygous de novo missense variants of SRP54 were recently identified in patients with congenital neutropenia (CN) who display symptoms that overlap with Shwachman-Diamond syndrome (SDS). Here, we investigate srp54 knockout zebrafish as the first
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bca97c945e9ba9d0e12560cb3cff53c7
https://hal.archives-ouvertes.fr/hal-03409719
https://hal.archives-ouvertes.fr/hal-03409719
Autor:
Martina Konantz, Sarah Bertels, Pauline Hanns, Anna M. Paczulla Stanger, Marlon Arnone, Claudia Lengerke, Parimala Sonika Godavarthy, Maximilian Christopeit
Publikováno v:
Cancers
Cancers, Vol 12, Iss 3742, p 3742 (2020)
Cancers, Vol 12, Iss 3742, p 3742 (2020)
Simple Summary Relapse after apparent remission remains a major cause of death in patients with acute myeloid leukemia (AML). On the cellular level, leukemia relapse is considered to emerge from subpopulations of therapy-resistant leukemic stem cells